**Background of S100A10 Antibody**
The S100A10 antibody is a research tool designed to detect S100A10. a member of the S100 calcium-binding protein family. S100A10. also known as p11. forms a heterotetrameric complex with annexin A2 (ANXA2), playing critical roles in cellular processes such as exocytosis, endocytosis, cytoskeletal dynamics, and cell migration. This protein is implicated in cancer progression, inflammation, and neurological disorders due to its involvement in regulating plasminogen activation, ion channel trafficking, and extracellular matrix remodeling.
S100A10 is overexpressed in various cancers, including breast, lung, and colorectal malignancies, where it promotes invasiveness and metastasis by enhancing proteolytic activity and cell motility. In the brain, S100A10 interacts with serotonin receptors and other signaling proteins, linking it to mood disorders like depression.
Antibodies targeting S100A10 are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study its expression, localization, and interaction partners. These antibodies aid in exploring its biological functions, diagnostic potential, and therapeutic relevance. Specific clones (e.g., monoclonal vs. polyclonal) vary in host species, epitope recognition, and cross-reactivity, necessitating validation for experimental contexts.
Research utilizing S100A10 antibodies has advanced understanding of its dual roles in physiological homeostasis and disease pathogenesis, highlighting its value as a biomarker or therapeutic target in oncology and neurology.